Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients

Alexis, John B.a; Martinez, Antonio E.a; Lutzky, Joseb

ORIGINAL ARTICLES
Buy

In order to determine whether imatinib mesylate (Gleevec), a tyrosine kinase inhibitor that binds the CD-117 (c-kit) receptor, may be of value in the treatment of malignant melanoma, an immunohistochemical analysis of 40 cases of primary and metastatic melanoma was undertaken. Thirty-five of the 40 cases showed 1+ or stronger labelling for CD-117 (up to a maximum of 4+). Three patients with neoplasms showing 4+ staining were selected for imatinib therapy. None responded. c-kit (CD-117) expression in melanoma appears to be common; however, the value of imatinib therapy remains to be proven.

aThe Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine

bThe Comprehensive Cancer Center, Mount Sinai Medical Center of Greater Miami and The University of Miami School of Medicine, Miami, FL, USA

Correspondence and requests for reprints to Dr Antonio E. Martinez, The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center of Greater Miami and The University of Miami School of Medicine, 4300 Alton Road, Blum Bldg, RM 201, Miami Beach, FL 33140 Miami, FL, USA

Tel: +1 305 674 2277; fax: +1 305 674 2999;

e-mail: antonio_martinez@bellsouth.net

Received 9 January 2004 Accepted (after revision) 25 October 2004

© 2005 Lippincott Williams & Wilkins, Inc.